Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Derm CasesDermatology / Surgical dermatology

Derm Cases · Dermatology / Surgical dermatology

OSCE — pearly facial nodule: basal cell carcinoma recognition, risk stratification and treatment pathway

An 8-minute OSCE station on nodular BCC morphology, dermoscopy clues, high-risk (H-zone) features, biopsy, surgical margins/Mohs indications, and options for superficial or advanced disease.

8 minosce2 min readVerification in progress

Target exams

NEET-PGINICETUSMLEPLABMRCP
On this page
Study tools

Target exams

NEET-PGINICETUSMLEPLABMRCP
Prompt
An 8-minute OSCE station on nodular BCC morphology, dermoscopy clues, high-risk (H-zone) features, biopsy, surgical margins/Mohs indications, and options for superficial or advanced disease.

Brief (to candidate)

A 68-year-old fair-skinned man has a slowly enlarging pearly papule on the left nasal ala for 14 months with a rolled border, arborising telangiectases and central crusting. He has cumulative sun exposure and a prior scalp BCC. You have 8 minutes to recognise the lesion, stratify risk, plan diagnosis and outline management.

Candidate instructions

  1. Describe nodular BCC morphology and key dermoscopy features.
  2. Identify high-risk site/subtype factors (H-zone, ill-defined margins).
  3. Plan appropriate biopsy and distinguish from SCC/melanoma mimics.
  4. Outline surgical options (standard excision margins vs Mohs).
  5. Mention non-surgical options for selected low-risk superficial BCC and Hedgehog inhibitors for advanced disease.
  6. Give safety-net and photoprotection advice.
[6]

Examiner checklist (mark each domain / 10)

DomainKey actions expected
RecognitionPearly papule/nodule, rolled border, arborising telangiectases, central ulceration ("rodent ulcer") on sun-exposed skin; rare metastasis but local destruction risk[2][4]
DermoscopyArborising vessels, blue-grey ovoid nests, spoke-wheel/leaf-like areas, ulceration; subtype-linked features support clinical diagnosis before histology[3]
Risk stratificationH-zone (periocular/perinasal/periauricular/ear/scalp), size, recurrent disease, morpheaform/infiltrative/micronodular subtypes = high-risk; consider Gorlin if multiple early BCCs[1][5]
DiagnosisDiagnostic biopsy (shave/punch appropriate for many BCC) confirming basaloid nests with peripheral palisading; full clinical photo-documentation
SurgeryLow-risk: excision with ~4–5 mm clinical margins; high-risk/critical-site/recurrent: prefer Mohs micrographic surgery for margin control and tissue sparing[1][2]
Non-surgical / advancedSelected low-risk superficial BCC: topical imiquimod / 5-FU / PDT where appropriate; radiotherapy selected cases (avoid in Gorlin); vismodegib/sonidegib for locally advanced/unresectable; immunotherapy after HHI failure in specialist care[1][5]
CommunicationExplain local aggressiveness vs low metastatic rate; photoprotection; whole-skin check; urgent pathway if H-zone or ill-defined scar-like plaque

Model key actions

  • Diagnose classic nodular BCC on the nasal ala using morphology ± dermoscopy.[2][3]
  • Flag H-zone high-risk site → prioritise Mohs discussion over casual observation.[1]
  • Plan tissue diagnosis then definitive margin-controlled treatment; discuss topical options only for appropriate superficial low-risk disease.[1][4]
  • Photoprotection, full skin examination, and follow-up for field UV damage.

Common errors

  • Dismissing a pearly ulcerated nodule as "just a spot" without biopsy.
  • Standard wide excision planning without recognising Mohs indications on the H-zone.
  • Using radiotherapy as first choice in suspected Gorlin syndrome.
  • Confusing pigmented BCC with melanoma and delaying appropriate biopsy pathway.
  • Ignoring cumulative field damage and second primary skin cancers.
[1] [2] [5]
References6ShowHide
  1. [1]Peris K, Fargnoli MC, Kaufmann R, et al. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023. European journal of cancer (Oxford, England : 1990), 2023.PMID 37604067
  2. [2]Heath MS, Bar A. Basal Cell Carcinoma. Dermatologic Clinics, 2023.PMID 36410973
  3. [3]Reiter O, Mimouni I, Dusza S, et al. Dermoscopic features of basal cell carcinoma and its subtypes: A systematic review. Journal of the American Academy of Dermatology, 2021.PMID 31706938
  4. [4]Kim DP, Kus KJB, Ruiz E. Basal Cell Carcinoma Review. Hematology/oncology clinics of North America, 2019.PMID 30497670
  5. [5]Dika E, Scarfì F, Ferracin M, et al. Basal Cell Carcinoma: A Comprehensive Review. International Journal of Molecular Sciences, 2020.PMID 32759706
  6. [6]Migden M, Farberg AS, Dummer R, et al. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma J Drugs Dermatol, 2021.PMID 33538567
PreviousOSCE — scarring hair loss: trichoscopy, biopsy margin, FFA and folliculitis decalvansDermatology / TrichologyNextOSCE — periorificial dermatitis: recognition, steroid withdrawal, and safe treatment ladderDermatology / Facial Dermatology